Novartis recently presented interim findings from the Sickle Cell World Assessment Survey (SWAY) at the 2019 American Society of Hematology (ASH) annual meeting this year, which highlighted new data around the global burden of the disease. Insights collected from over 2,100 patients and 360 health care providers evaluated the impact of the disease on patients and families, helping to inform the management of this debilitating disease.

Notably, patients reported a much higher number of vaso-occlusive crises (VOCs) than current published data, which suggests that VOCs may be …

• Once-daily QMF149 met primary endpoint of lung function improvement and key secondary endpoint of asthma control improvement versus mometasone furoate¹
   
• QMF149 showed improvement in peak expiratory flow, exacerbation rates, rescue medication use versus mometasone furoate among other secondary endpoints¹   
   
• Improvement in lung function was observed in high dose QMF149 versus a high dose LABA/ICS standard-of-care in certain additional secondary endpoints¹ 

…

• Uniquely positioned with global scale, focus on innovative medicines, diversification across therapeutic areas and exposure to cutting-edge platforms
• 60 projects in Phase 2 pipeline with 10+ advancing into Phase 3 or pivotal trials each year in 2020 and 2021; over 90% projected to be first-in-class or first-in-indication
• Emerging assets address areas of high unmet need including iscalimab in transplant and Sjögren’s syndrome, LNP023 in renal diseases and PNH, MBG453 in MDS, and TQJ230 in cardiovascular risk reduction
• …

On Wednesday December 4, 2019 Amazon Web Services announced a strategic collaboration with Novartis that will leverage AWS’s broadest portfolio of cloud services to build an enterprise-wide data and analytics platform that will transform business operations.  Starting within Novartis Technical Operations, this multiyear alliance aims to put real-time analytics in the hands of associates, empowering them to make better business decisions and increase efficiencies across manufacturing processes and supply chain.

…

At the American Society of Hematology (ASH) Annual Meeting & Exposition and the San Antonio Breast Cancer Symposium (SABCS) in December, Novartis will present more than 180 abstracts. 

We have a rich history of research and development (R&D) in the areas of hematology and oncology. For decades, we have leveraged learnings from both successes and setbacks to broaden our understanding of unmet patient needs, and identify ways to help transform the standard of care for those with blood disorders and cancer. Some of these scientific insights, combined with the information and …